Objective:To investigate the effects of rosuvastatin combined with metoprolol succinate on apolipoproteins,non-high-density lipoprotein cholesterol(non-HDL-C)/high-density lipoprotein cholesterol(HDL-C)ratio,and liver function in patients with at-rial fibrillation.Methods:102 patients with atrial fibrillation were divided into a control group and a combination group based on differ-ent treatment regimens,with 51 cases in each group.The control group was treated with metoprolol succinate,while the combination group received rosuvastatin in addition to the treatment given to the control group.Both groups were treated continuously for 6 months.Blood lipids,inflammation markers,liver function,atrial fibrillation episodes,cardiac function,treatment efficacy,and adverse reactions were recorded and compared between the two groups.Results:After treatment,the levels of apolipoprotein A(ApoA)and non-HDL-C/HDL-C in the combination group were lower than those in the control group,while the level of apolipoprotein B(ApoB)was higher in the combination group(P＜0.05).The levels of high-sensitivity C-reactive protein(hs-CRP)and interleukin-6(IL-6)in the combi-nation group were also lower than those in the control group(P＜0.05).There was no significant difference in alanine aminotransferase(ALT)and aspartate aminotransferase(AST)levels between the two groups(P＞0.05).After treatment,the duration and frequency of atrial fibrillation episodes in the combination group were lower than those in the control group(P＜0.05),the left atrial volume(LAV)in the combination group was lower,and the left atrial ejection fraction(LAEF)was higher than in the control group(P＜0.05),the effective treatment rate in the combination group was higher than in the control group(P＜0.05).The incidence of adverse reactions was not significantly different between the two groups(P＞0.05).Conclusion:The treatment with rosuvastatin combined with metopro-lol succinate is beneficial in reducing blood lipids and inflammation levels in patients with atrial fibrillation,improving cardiac function,demonstrating significant treatment efficacy,and showing good clinical outcomes.